Drug Type Fusion protein |
Synonyms |
Target |
Mechanism DR4 modulators(Tumor necrosis factor receptor superfamily member 10A modulators), DR5 modulators(Tumor necrosis factor receptor superfamily member 10B modulators), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | - | 21 Sep 2022 |